Literature DB >> 28829241

Construction and Immunogenicity Analysis of Whole-Gene Mutation DNA Vaccine of Aleutian Mink Virus Isolated Virulent Strain.

Dongxu Liu1,2, Jianming Li1, Kun Shi1, Fanli Zeng1, Ying Zong1, Xue Leng1, Huijun Lu3, Rui Du1.   

Abstract

Aleutian mink disease (AD) is a chronic viral infection that causes autoimmune disorders in minks and presents a significant economic burden on mink farming. Despite the substantial challenges presented by AD, no effective vaccine is available and only partial protection has been achieved. We constructed a whole-gene nucleic acid vaccine from an isolated virulent Aleutian mink disease virus (ADV) strain (pcDNA3.1-ADV). Based on this whole-gene nucleic acid vaccine, we generated truncated mutant constructs by removing portions of the ADV VP2 gene using overlap extension polymerase chain reaction. pcDNA3.1-ADV-428 lacks nucleotides encoding VP2 amino acid residues 428-466, and pcDNA3.1-ADV-428-487 harbors additional deletion of nucleotides coding for VP2 amino acid residues 487-501. We also generated nucleic acid vaccines for the ADV NS1 gene, truncated ADV NS1 gene, ADV VS2 gene, and truncated ADV VS2 gene: pcDNA3.1-NS1, pcDNA3.1-NS1-D, pcDNA3.1-VP2, and pcDNA3.1-VP2-D, respectively. The immunogenicity of the seven DNA vaccines was confirmed by immunofluorescent evaluation. Sixty female minks were divided into 10 groups: seven groups were immunized with the DNA vaccines, one control group was injected with phosphate-buffered saline, one group was immunized with pcDNA3.1 empty vector, and one group was immunized with inactivated ADV-G virus. ADV antibody levels, percentage of CD8+ cells in blood, and levels of γ-globulin and circulating immune complexes in the serum were evaluated longitudinally over 36 weeks after ADV challenge. Minks that were immunized with the pcDNA3.1-ADV-428-487 nucleic acid vaccine produced ADV antibodies. After ADV challenge, the minks immunized with pcDNA3.1-ADV-428-487 nucleic acid vaccine had lower γ-globulin content and lower CIC in serum compared to other immunization groups. Although the pcDNA3.1-ADV-428-487 nucleic acid vaccine did not demonstrate complete protection against ADV, it demonstrated marked efficacy and could potentially be used as a vaccine to prevent losses in mink populations due to ADV. Discovery of effective means to vaccinate mink against ADV will not only improve overall health of mink populations but will also reduce the economic impact of ADV.

Entities:  

Keywords:  Aleutian mink disease; Aleutian mink disease virus; immunogenicity; nucleic acid vaccine

Mesh:

Substances:

Year:  2017        PMID: 28829241     DOI: 10.1089/vim.2017.0044

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  6 in total

1.  Dose response of black American mink to Aleutian mink disease virus.

Authors:  A Hossain Farid; Irshad Hussain
Journal:  Immun Inflamm Dis       Date:  2020-03-13

2.  Detection of selection signatures for response to Aleutian mink disease virus infection in American mink.

Authors:  Karim Karimi; A Hossain Farid; Sean Myles; Younes Miar
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

3.  Aptamer-targeting of Aleutian mink disease virus (AMDV) can be an effective strategy to inhibit virus replication.

Authors:  Taofeng Lu; Hui Zhang; Jie Zhou; Qin Ma; Wenzhuo Yan; Lili Zhao; Shuguang Wu; Hongyan Chen
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

4.  Dietary supplementation of Ascophylum nodosum improved kidney function of mink challenged with Aleutian mink disease virus.

Authors:  A Hossain Farid; Nancy J Smith
Journal:  BMC Vet Res       Date:  2020-11-30       Impact factor: 2.741

5.  Long-term antibody production and viremia in American mink (Neovison vison) challenged with Aleutian mink disease virus.

Authors:  A Hossain Farid; Irshad Hussain; Priyanka P Rupasinghe; Jancy Stephen; Irin Arju
Journal:  BMC Vet Res       Date:  2022-10-03       Impact factor: 2.792

Review 6.  AMDV Vaccine: Challenges and Perspectives.

Authors:  Nathan M Markarian; Levon Abrahamyan
Journal:  Viruses       Date:  2021-09-14       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.